Regeneron's Immunotherapy Study for Advanced Lung Cancer Shows Promising Results

Regeneron Pharmaceuticals is conducting a Phase 1b/2 study to evaluate the safety and efficacy of cemiplimab, an anti-PD1 antibody, in combination with other antibodies (S095018, S095024, or S095029) in patients with advanced non-small cell lung cancer. The study aims to determine the recommended dose and assess the efficacy of the combinations. If results are positive, it could boost Regeneron's stock performance and position the company competitively within the immunotherapy sector.

Regeneron Pharmaceuticals ((REGN)) has announced an update on its ongoing clinical study, titled "A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression" [1]. The study aims to evaluate the safety and efficacy of the anti-PD1 antibody, cemiplimab, in combination with other antibodies (S095018, S095024, or S095029) in patients with advanced NSCLC. The primary goal is to determine the recommended dose and assess the efficacy of these combinations.

The study began on August 7, 2024, and is currently ongoing. It follows a randomized, parallel assignment model with no masking. The outcome of this study could significantly impact Regeneron’s market position, potentially boosting its stock performance if results are positive. It also positions Regeneron competitively within the immunotherapy sector, which is witnessing rapid advancements.

Regeneron Pharmaceuticals is known for its antibody-based therapies targeting a range of disease areas, including eczema, macular degeneration, and cancer. Its top-selling product, Dupixent, generated $14.2 billion in global net sales in 2024, up 22% from the prior year. Another blockbuster product, Eylea, generated $6 billion in U.S. net sales in 2024. Despite recent challenges, such as competition from biosimilar versions and slower-than-expected adoption of Eylea HD, Regeneron continues to advance its pipeline with 45 product candidates in clinical development and several regulatory approvals expected in 2025.

The company reported a 12% increase in net income from the prior-year quarter to $809 million in the first quarter of 2025, despite a 3.7% year-over-year decline in revenue to $3.03 billion. Regeneron has also initiated a dividend, which could be a worthy addition for investors seeking long-term returns and dividend income.

Regeneron Pharmaceuticals' stock has shown resilience, leading the Nasdaq 100 index in early trading on July 2, 2025, with a 3.6% gain, despite a year-to-date decline of 20.7%. The company's continued investment in innovation and its strong pipeline position it well for future growth.

References:
[1] https://www.tipranks.com/news/company-announcements/regenerons-promising-immunotherapy-study-for-advanced-lung-cancer